![](/images/graphics-bg.png)
Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
Joint Authors
Walker, Kristy J.
Lee, Young R.
Klar, Amanda R.
Source
Canadian Journal of Infectious Diseases and Medical Microbiology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-02-08
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
Highly resistant Gram-negative bacterial infections are associated with high mortality.
Increasing resistance to standard therapy illustrates the need for alternatives when treating resistant organisms, especially extended-spectrum beta-lactamase- (ESBL-) producing Enterobacteriaceae.
Methods.
A retrospective chart review at a community hospital was performed.
Patients who developed ESBL-producing infections were included.
Patients less than eighteen years old, who were pregnant, or who were incarcerated were excluded.
The primary outcome was hospital mortality.
The secondary outcomes included intensive care unit (ICU) mortality, ICU length of stay, and hospital length of stay.
Results.
113 patients with ESBL-producing infections met the criteria for review.
Hospital mortality: carbapenem (16.6%), cefepime (0%), and levofloxacin (15.3%) (p=0.253).
ICU mortality: carbapenem (4.5%), cefepime, (0%), and levofloxacin (3.7%) (p=0.616).
Mean ICU and hospital length of stay: carbapenem (9.8 ± 16, 12.1 ± 1 days), cefepime (7.8 ± 6, 11.1 ± 10.5 days), and levofloxacin (5.4 ± 4.1, 11.1 ± 10.4 days) (p=0.805,0.685).
No predictors were clearly found between the source of infection and mortality.
Conclusion.
Cefepime or levofloxacin can be a potential alternative agent for infections with ESBL-producing Enterobacteriaceae, and larger clinical trials investigating these outcomes are warranted.
American Psychological Association (APA)
Walker, Kristy J.& Lee, Young R.& Klar, Amanda R.. 2018. Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1131171
Modern Language Association (MLA)
Walker, Kristy J.…[et al.]. Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1131171
American Medical Association (AMA)
Walker, Kristy J.& Lee, Young R.& Klar, Amanda R.. Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems. Canadian Journal of Infectious Diseases and Medical Microbiology. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1131171
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1131171